Buy & Sell Intuit Inc. (INTU) – Intuit Inc. Price Today
Aura AI Summary
Key Stats
- $90.69BMarket Cap
- TechnologySector
- -36.75%3M Drawdown
- $89.14BEnterprise Value
- 1.45%Dividend Yield
- 69% Buy | 31% SellTrading Activity
- 65 daysTypical Hold Time
Intuit Inc. (INTU) is currently valued at a market capitalization of $90.69B, with an enterprise value of $89.14B. Over the past 52 weeks, Intuit Inc. has traded between a low of $304.35 and a high of $807.39, highlighting its annual price range. Over the past three months, Intuit Inc. has recorded a drawdown of -36.75%, reflecting recent price volatility. Intuit Inc. offers a dividend yield of 1.45%, with the most recent dividend of $1.20 paid on 09 Apr 26. On average, investors hold Intuit Inc. for approximately 65 days, indicating typical investor behavior on the platform.
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Most Recent News
Exicure resolves Nasdaq filing delay, regains compliance after late 10-Q submission
Exicure, Inc. received a Nasdaq notice for delayed filing of its Q1 2026 Form 10-Q due to changes in financial staff and procedures. The company filed the report on May 29, 2026, and believes it has restored compliance with Nasdaq rules. Exicure is c...

Carahsoft hosts GovExperience Summit to advance government digital service and citizen engagement.
Carahsoft Technology Corp. is hosting the Annual GovExperience Summit on June 2, 2026, in Reston, Virginia, focusing on improving government service delivery and customer experience through emerging technologies. The event gathers leaders from federa...

Kuehn Law investigates Vistagen Therapeutics for alleged misrepresentation in clinical trial risks.
Kuehn Law, PLLC is investigating whether Vistagen Therapeutics' officers and directors breached their duties by misrepresenting risks in their Social Anxiety Disorder clinical trials. The lawsuit claims insiders failed to disclose high placebo respon...
